Whole-exome sequencing revealed mutations in BCR-involved proteins BTK and PLCγ2 in ~80% of CLL patients with acquired resistance to ibrutinib (7, 96), however, some studies have reported a much lower frequency of these mutations (97, 98). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.